NantKwest rises 21% on ImmunityBio merger deal

Dec. 21, 2020 6:24 AM ETImmunityBio, Inc. (IBRX)By: Mamta Mayani, SA News Editor
  • NantKwest (NK), up 21% premarket, and privately-held ImmunityBio have entered into an agreement to merge in a stock-for-stock transaction. The combination will create an immunotherapy and cell therapy company focused on oncology and infectious disease.
  • Together, ImmunityBio and NantKwest will have a broad, clinical-stage pipeline – including 13 assets in clinical trials and 11 in Phase II to III – as well as a robust early stage pipeline to address other difficult to treat cancers.
  • The transaction is structured as a tax-free 100% stock-for-stock merger, with ImmunityBio to reverse merge with NantKwest.
  • Under the terms of the agreement, ImmunityBio shareholders will receive a fixed exchange ratio of 0.8190 shares of NantKwest for each share of ImmunityBio owned.
  • Upon completion of the transaction, ImmunityBio and NantKwest shareholders will own ~72% and ~28% of the combined company, respectively.
  • The transaction is expected to close in Q1 2021. The combined company will assume the ImmunityBio name and continue to be listed on the Nasdaq under the ticker symbol 'IBRX'.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.